Nothing Special   »   [go: up one dir, main page]

Xiao et al., 2020 - Google Patents

Germline variant burden in multidrug resistance transporters is a therapy‐specific predictor of survival in breast cancer patients

Xiao et al., 2020

View PDF
Document ID
13194474104677148281
Author
Xiao Q
Zhou Y
Winter S
Büttner F
Schaeffeler E
Schwab M
Lauschke V
Publication year
Publication venue
International Journal of Cancer

External Links

Snippet

Multidrug resistance due to facilitated drug efflux mediated by ATP‐binding cassette (ABC) transporters is a main cause for failure of cancer therapy. Genetic polymorphisms in ABC genes affect the disposition of chemotherapeutics and constitute important biomarkers for …
Continue reading at onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology

Similar Documents

Publication Publication Date Title
Yee et al. Influence of transporter polymorphisms on drug disposition and response: a perspective from the international transporter consortium
Xiao et al. Germline variant burden in multidrug resistance transporters is a therapy‐specific predictor of survival in breast cancer patients
Low et al. Breast cancer: The translation of big genomic data to cancer precision medicine
Bhatia Genetics of anthracycline cardiomyopathy in cancer survivors: JACC: CardioOncology state-of-the-art review
Wheeler et al. Cancer pharmacogenomics: strategies and challenges
Argyriou et al. Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics
Sheng et al. MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case–control studies
Baker et al. Pharmacogenetic pathway analysis of docetaxel elimination
Yamakawa et al. Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia
Weiss New approaches to personalized medicine for asthma: Where are we?
Fowler et al. A UGT2B10 splicing polymorphism common in african populations may greatly increase drug exposure
Russell et al. Pharmacogenomics in the era of next generation sequencing–from byte to bedside
Woo et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma
Chen et al. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients
Han et al. Evaluating genetic variants associated with breast cancer risk in high and moderate-penetrance genes in Asians
Han et al. A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer
Wang et al. Functional variant in the SLC22A3-LPAL2-LPA gene cluster contributes to the severity of coronary artery disease
Li et al. The roles of variants in human multidrug resistance (MDR1) gene and their haplotypes on antiepileptic drugs response: a meta-analysis of 57 studies
Chu et al. Association of ABCB1 and FLT3 polymorphisms with toxicities and survival in Asian patients receiving sunitinib for renal cell carcinoma
Franke et al. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes
Erculj et al. The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma
Neřoldová et al. Rare variants in known and novel candidate genes predisposing to statin-associated myopathy
Sohn et al. Whole exome sequencing for the identification of CYP3A7 variants associated with tacrolimus concentrations in kidney transplant patients
Ono et al. Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions
Wang et al. Clustered Mendelian randomization analyses identify distinct and opposing pathways in the association between genetically influenced insulin-like growth factor-1 and type 2 diabetes mellitus